EcoDrugPlus

Dopamine Receptor D3

Ensembl ID : ENSPNYG00000004353
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSPNYG00000011441
Gene Symbol: DRD4
3 Cross references
165 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSPNYG00000002773
Gene Symbol: DRD5
2 Cross references
147 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSPNYG00000006796
Gene Symbol: LOC102194177
3 Cross references
200 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSPNYG00000023702
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl Nine Homolog 2-Like

Ensembl ID : ENSPNYG00000018789
Gene Symbol: LOC102214078
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSPNYG00000013701
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSPNYG00000014374
Gene Symbol: EGLN3
3 Cross references
198 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSPNYG00000011765
Gene Symbol: EPAS1
3 Cross references
210 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSPNYG00000007489
Gene Symbol: LOC102198610
3 Cross references
197 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSPNYG00000003897
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSPNYG00000012650
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).